Compare LQDA & TGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | TGLS |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2020 | 2011 |
| Metric | LQDA | TGLS |
|---|---|---|
| Price | $37.80 | $45.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $41.00 | ★ $67.50 |
| AVG Volume (30 Days) | ★ 1.1M | 370.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ 3.42 |
| Revenue | $158,320,000.00 | ★ $370,984,000.00 |
| Revenue This Year | $278.87 | $13.56 |
| Revenue Next Year | $57.13 | $9.67 |
| P/E Ratio | ★ N/A | $12.88 |
| Revenue Growth | ★ 1031.18 | 17.98 |
| 52 Week Low | $11.85 | $39.53 |
| 52 Week High | $46.67 | $90.34 |
| Indicator | LQDA | TGLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 55.32 |
| Support Level | $31.75 | $44.26 |
| Resistance Level | $39.19 | $47.37 |
| Average True Range (ATR) | 2.12 | 1.90 |
| MACD | 0.09 | 0.33 |
| Stochastic Oscillator | 37.52 | 95.35 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.